Atrium Medical presents benefits of its COCTAIL research Atrium Medical Company is proud to announce the launch of the final outcomes of the COCTAIL Research, a clinical research comparing community administration of an anti-platelet medicine with the business’s proprietary infusion balloon technology. Dr. Francesco Prati of San Giovanni Medical center and the European Imaging Laboratory in Rome, Italy provided the outcomes of the study at the latest TCT meeting held in SAN FRANCISCO BAY AREA, California vardenafil vs viagra . Related StoriesGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningNew UCLA research talks about primary care medical house in reducing childrens' repeat appointments to hospitalsPatients provided animal-assisted therapy at UCLA HealthThis to begin its kind coronary occlusion research is a multi-centered, randomized, single blinded, controlled medical trial comparing regional coronary administration of the medication abciximab through helpful information catheter compared with regional coronary administration of abciximab using Atrium’s novel infusion balloon catheter..
Atrial fibrillation associated with improved hospitalization in heart failure patients Individuals with atrial fibrillation, common in people that have advanced chronic heart failing, have an elevated risk of hospitalization because of heart failing, according to new study from researchers in the University of Alabama in Birmingham . The results, published in June in the European Center Journal, also claim that atrial fibrillation isn’t associated with an elevated threat of death in heart failing patients, contradicting earlier assumptions. ‘Our findings display that the current presence of atrial fibrillation in center failure patients didn’t increase their threat of death, as provides been suggested previously, but did raise the risk of hospitalization because of worsening heart failing,’ stated Mustafa Ahmed, M.D., a physician-scientist at the UAB American Table of Internal Medicine Analysis Pathway System and the study’s business lead investigator.